Immuron Ltd — Capital/Financing Update 2015

Aug 31, 2015

==> picture [221 x 62] intentionally omitted <==

Immuron Applies for OTCQB Listing

1 September 2015, Melbourne, Australia: Immuron Limited (ASX:IMC) is pleased to announce that as a result of the recent roadshow in the US and the interest which this attracted, the Company has submitted the necessary filing documents to upgrade its American Depository Receipts (ADRs) program of OTC ‘pink sheets’ to an OTCQB Listing. OTCQB is recognised as an Established Public Markets platform by the US Securities & Exchange Commission (SEC).

The Over-The-Counter (OTC) market is a decentralised market where securities not listed on a major exchange are traded directly and electronically by market participants. Through the OTCQB listing, Immuron will have a direct link to a diverse network of brokers and dealers who can provide liquidity and execution services for the Company’s securities in the US.

This is seen by the Board of Immuron as the next step in the expansion and diversification of Immuron’s shareholder investment base, particularly as the US market continues to recognise the value proposition which Australian biotechnology companies, such as Immuron, offer to prospective investors and shareholders.

The OTCQB Listing will be the first step in the Company’s plan to gain increased exposure to the US market.

The Company intends to apply for a full US National Exchange listing in the coming months.

Contact:

Dr Roger Aston Mr Peter Anastasiou Non-Executive Chairman Vice Chairman Ph:+61 (0)3 9824 5254 Ph:+61 (0)419 511 604

ABOUT IMMURON

Immuron Ltd (ASX:IMC) is a Microbiom company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The company currently markets Travelan® for the prevention of travellers’ diarrhoea, its lead product candidate IMM-124E is in Phase 2 clinical trials for NASH and ASH, and it has a preclinical immunotherapy pipeline targeting immune-related diseases with unmet needs.

Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), Monash University (Australia) and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) (Australia).

Suite 1, 1233 High Street Armadale, Victoria AUSTRALIA 3143

www.immuron.com ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735